A detailed history of Axa S.A. transactions in Savara Inc stock. As of the latest transaction made, Axa S.A. holds 1,051,432 shares of SVRA stock, worth $3.36 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,051,432
Previous 1,051,135 0.03%
Holding current value
$3.36 Million
Previous $4.24 Million 5.24%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.96 - $5.07 $1,176 - $1,505
297 Added 0.03%
1,051,432 $4.46 Million
Q2 2024

Aug 14, 2024

SELL
$3.66 - $5.34 $1.02 Million - $1.49 Million
-279,300 Reduced 20.99%
1,051,135 $4.24 Million
Q1 2024

May 15, 2024

SELL
$4.19 - $5.59 $1.75 Million - $2.33 Million
-417,238 Reduced 23.87%
1,330,435 $6.63 Million
Q4 2023

Jul 16, 2024

BUY
$3.18 - $4.9 $1.33 Million - $2.04 Million
417,238 Added 31.36%
1,747,673 $8.21 Million
Q4 2023

Feb 14, 2024

SELL
$3.18 - $4.9 $134,434 - $207,147
-42,275 Reduced 2.36%
1,747,673 $8.21 Million
Q3 2023

Nov 14, 2023

SELL
$2.97 - $3.88 $1.47 Million - $1.93 Million
-496,455 Reduced 21.71%
1,789,948 $6.77 Million
Q2 2023

Aug 14, 2023

SELL
$1.69 - $3.24 $917,546 - $1.76 Million
-542,927 Reduced 19.19%
2,286,403 $7.29 Million
Q1 2023

May 15, 2023

SELL
$1.6 - $2.82 $925,691 - $1.63 Million
-578,557 Reduced 16.98%
2,829,330 $5.52 Million
Q4 2022

Feb 14, 2023

SELL
$1.11 - $1.64 $20,344 - $30,057
-18,328 Reduced 0.53%
3,407,887 $5.28 Million
Q3 2022

Feb 14, 2023

BUY
$1.36 - $1.88 $20,040 - $27,703
14,736 Added 0.43%
3,426,215 $4.87 Million
Q3 2022

Nov 14, 2022

BUY
$1.36 - $1.88 $20,040 - $27,703
14,736 Added 0.43%
3,426,215 $5.31 Million
Q2 2022

Feb 14, 2023

SELL
$1.1 - $1.58 $72,988 - $104,837
-66,353 Reduced 1.91%
3,411,479 $5.19 Million
Q2 2022

Aug 15, 2022

SELL
$1.1 - $1.58 $72,988 - $104,837
-66,353 Reduced 1.91%
3,411,479 $5.19 Million
Q1 2022

Feb 14, 2023

BUY
$1.05 - $1.36 $54,197 - $70,199
51,617 Added 1.51%
3,477,832 $4.56 Million
Q1 2022

May 13, 2022

BUY
$1.05 - $1.36 $38 - $50
37 Added 0.0%
3,477,832 $4.56 Million
Q4 2021

Feb 14, 2022

BUY
$1.04 - $1.34 $428,990 - $552,737
412,491 Added 13.46%
3,477,795 $4.31 Million
Q3 2021

Nov 15, 2021

BUY
$1.18 - $1.64 $133,427 - $185,441
113,074 Added 3.83%
3,065,304 $4.23 Million
Q2 2021

Aug 13, 2021

SELL
$1.51 - $2.29 $338,529 - $513,399
-224,192 Reduced 7.06%
2,952,230 $5.02 Million
Q1 2021

May 14, 2021

BUY
$1.17 - $2.33 $1.5 Million - $2.98 Million
1,280,868 Added 67.57%
3,176,422 $6.61 Million
Q4 2020

Feb 12, 2021

BUY
$1.0 - $1.47 $491,035 - $721,821
491,035 Added 34.96%
1,895,554 $2.18 Million
Q3 2020

Nov 13, 2020

SELL
$1.09 - $2.21 $8,412 - $17,056
-7,718 Reduced 0.55%
1,404,519 $1.53 Million
Q2 2020

Aug 14, 2020

BUY
$1.8 - $3.05 $128,233 - $217,285
71,241 Added 5.31%
1,412,237 $3.52 Million
Q1 2020

May 15, 2020

BUY
$1.91 - $4.08 $2.56 Million - $5.47 Million
1,340,996 New
1,340,996 $2.84 Million

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.